Please login to the form below

Not currently logged in
Email:
Password:

Dr Reddy's

This page shows the latest Dr Reddy's news and features for those working in and with pharma, biotech and healthcare.

Indivior slumps as patent dispute rises US generic spectre

Indivior slumps as patent dispute rises US generic spectre

Indivior said it plans to appeal the decision, which held that three US patents on Suboxone were valid but that a generic from Indian drugmaker Dr Reddy's Laboratories drug does ... He said that Dr Reddy's has not yet been granted FDA approval for its

Latest news

  • Fresenius Kabi buys Akorn and Merck's biosimilar businesses Fresenius Kabi buys Akorn and Merck's biosimilar businesses

    Adding in Merck's biosimilars business takes it right back into the biotech sphere. ... Merck kicked off its biosimilar programme in 2012 via an agreement with India's Dr Reddy's Laboratories at a time when the company was facing patent expiries on some

  • Merck confirms sale of biosimilar division Merck confirms sale of biosimilar division

    The German group kicked off its biosimilar programme in 2012 via an agreement with India's Dr Reddy's Laboratories, at a time when the company was facing patent expiries on ... At the time the Dr Reddy's deal was announced the biosimilars market was a

  • Dr Reddy's brings its generics portfolio to France Dr Reddy's brings its generics portfolio to France

    Dr Reddy's brings its generics portfolio to France. Continues the European roll-out of its oncology and anti-infective products. ... Dr Reddy's Laboratories will next month launch its generics portfolio in France as it continues to expand its European

  • India denies Vertex patent on cystic fibrosis drug Orkambi India denies Vertex patent on cystic fibrosis drug Orkambi

    India's Kolkata Patent Office declined to approve the Indian version of this patent - first filed in 2008 - on the grounds that most of the claims are obvious and do not ... The patent was opposed by the Indian Pharmaceutical Alliance (IPA), a trade

  • Dr. Reddy’s enters €118m product agreement with UCB in India Dr. Reddys enters €118m product agreement with UCB in India

    Dr. Reddy’ s enters 118m product agreement with UCB in India. ... Portfolio acquisition will expand firm’ s therapy footprint. Dr. Reddy's Laboratories has entered a 118m (INR 800 Crores) definitive agreement to acquire a select portfolio of

More from news
Approximately 3 fully matching, plus 59 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Dr Reddy's has expanded its collaboration with Amgen in India adding three approved products: Xgeva for treating bone metastases, Vectibix in colorectal cancer therapy and Prolia for osteoporosis. ... Upfront $80m plus $830m in milestones [ex S. Korea].

  • Deal Watch June 2016 Deal Watch June 2016

    The three deals with Mayne Pharma, Impax Laboratories and Dr Reddy's, for a combined value of over $1.5bn, cover portfolios of marketed and approved generic drugs, drugs currently pending ... acquisition assets/ return of rights. 586. Teva and Allergan/

  • Deal Watch March 2016 Deal Watch March 2016

    Two deals involved products at a later stage of development: Dr Reddy's licence for Xenoport's phase II product XP23829 for plaque psoriasis, and Ipsen's licence for Exelixis's ... Collaboration – development. $595. Xenoport/ Dr Reddy's. XP-23829 for

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    Medius Deal Watch table for April 2015. The top major pharma mergers, acquisitions and collaborations during the month continued pharma's love affair with oncology. ... 151. UCB/ Dr. Reddy's. Business acquisition. Dermatology, respiratory and paediatric

  • Pharma deals in April 2015 Pharma deals in April 2015

    Dr Reddy's, Menarini and Cipher Pharmaceuticals have acquired or licensed rights to products in South Asia, Asia Pacific (ex-Japan) and North America and Mexico, respectively. ... Previously rumoured, Dr Reddy's acquires rights to dermatology,

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Dr Reddy's makes senior changes as US generics head exits Dr Reddy's makes senior changes as US generics head exits

    Dr Reddy's makes senior changes as US generics head exits. UmangVohra will be replaced by Alok Sonig. ... Dr Reddy's has appointed Alok Sonig to be its new head of North America generics to take over from Umang Vohra (pictured).

  • MedImmune appoints Dr Anand Subramony MedImmune appoints Dr Anand Subramony

    While at Novartis Dr Subramony established and headed company's novel delivery technologies and therapeutics group. ... Prior to that he held leadership positions at Dr. Reddy's Laboratories in Bridgewater, New Jersey and Johnson &Johnson/Alza

  • Pegasus recruits corporate services lead Pegasus recruits corporate services lead

    His team's first priority, Mackenzie-Reid added, was to ensure the market understands Pegasus'new proposition. ... Clients include Bayer, Novo Nordisk, Fittleworth, Dr Reddy's and Holland &Barrett.

  • New global head of HR for Dr Reddy’s New global head of HR for Dr Reddys

    New global head of HR for Dr Reddy’ s. Sripada Chandrasekhar joins from IBM. ... Chakraborty remains with Dr Reddy's, and has retained all but the HR element of his role.

  • Dr Reddy’s appoints Umang Vohra to lead US business Dr Reddys appoints Umang Vohra to lead US business

    Dr Reddy’ s appoints Umang Vohra to lead US business. Will be replaced as chief financial officer by Saumen Chakraborty. ... Indian generics company Dr Reddy's Laboratories has appointed Umang Vohra as the new head of its North American business.

More from appointments
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics